Find recruiting clinical trials for cervical cancer in the UK — including immunotherapy combinations with pembrolizumab, novel antibody-drug conjugates, HPV-targeted therapeutic vaccines, and next-generation chemoradiotherapy protocols. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Cancer confined to the cervix or upper vagina
Standard: Cone biopsy, trachelectomy, or radical hysterectomy with lymph node dissection
Cancer involving parametria, pelvic wall, or adjacent structures
Standard: Concurrent cisplatin-based chemoradiotherapy, brachytherapy, pembrolizumab combination
Spread beyond the pelvis or disease returning after treatment
Standard: Pembrolizumab + cisplatin/paclitaxel + bevacizumab, tisotumab vedotin, palliative radiotherapy
Post-treatment follow-up and preventing recurrence
Standard: Regular surveillance imaging, HPV testing, management of treatment side effects (lymphoedema, sexual health, menopause)
Pembrolizumab with chemoradiotherapy for locally advanced disease, novel PD-1/CTLA-4 bispecific antibodies, and TIL (tumour-infiltrating lymphocyte) cell therapy for patients who progress on checkpoint inhibitors.
TROP2 and HER3-directed ADCs in development for cervical cancer after pembrolizumab failure. Tisotumab vedotin (targeting tissue factor) is the first-in-class ADC now approved and being trialled in earlier lines.
Novel therapeutic vaccines designed to induce T-cell responses against HPV-16 and HPV-18 E6/E7 oncoproteins. These are being tested as monotherapy for high-grade cervical intraepithelial neoplasia and in combination with checkpoint inhibitors for invasive cancer.
MRI-guided adaptive brachytherapy protocols, hypofractionation schedules, and radiosensitiser drugs aimed at improving local control while reducing side effects on the bladder and rectum.
Loading trials from ClinicalTrials.gov...
Yes. Many trials recruit patients with recurrent or metastatic cervical cancer after first-line treatment. These studies test new immunotherapy combinations and antibody-drug conjugates for advanced disease.
Tisotumab vedotin is an antibody-drug conjugate targeting tissue factor on cervical cancer cells. UK centres are participating in trials testing it alone and in combination with pembrolizumab for recurrent cervical cancer.
Yes. Several trials are testing therapeutic HPV vaccines designed to boost the immune system's ability to recognise and destroy HPV-infected cancer cells, both for early-stage and advanced disease.
Pembrolizumab is now NICE-approved for some cervical cancer indications, but trials are testing it earlier in the treatment pathway — combined with chemoradiotherapy for locally advanced disease — which you may be able to access through a trial.
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.